BIOA
BioAge Labs, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.59
+0.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.4M | 9.0M | — | — | — |
| Cost of Revenue | 63.0K | — | — | — | — |
| Gross Profit | 10.3M | 9.0M | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 87.8M | 74.0M | 59.0M | 33.9M | 30.5M |
| SG&A Expense | 28.8M | 27.8M | 19.2M | 14.5M | 9.4M |
| General & Admin Expense | 28.8M | 27.8M | 19.2M | 14.5M | 9.4M |
| Selling & Marketing Expense | (63.0K) | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 116.6M | 101.8M | 78.2M | 48.4M | 40.0M |
| Cost and Expenses | 116.6M | 101.8M | 78.2M | 48.4M | 40.0M |
| Operating Income (EBIT) | (106.3M) | (92.8M) | (78.2M) | (48.4M) | (40.0M) |
| Non-Operating | |||||
| Interest Income | 12.7M | 13.1M | 9.6M | 2.4M | 465.0K |
| Interest Expense | 281.0K | 697.0K | 2.4M | 7.8M | 241.0K |
| Net Interest Income | 12.4M | 12.4M | 7.3M | (5.4M) | 224.0K |
| Other Non-Op Income/Expense | 11.8M | 12.2M | 7.1M | (15.5M) | 247.0K |
| Non-Operating Income (excl Interest) | (12.1M) | (12.9M) | (9.5M) | 7.7M | (488.0K) |
| EBT (Pre-Tax Income) | (94.5M) | (80.6M) | (71.1M) | (63.9M) | (39.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (94.5M) | (80.6M) | (71.1M) | (63.9M) | (39.7M) |
| Earnings from Cont. Ops | (94.5M) | (80.6M) | (71.1M) | (63.9M) | (39.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (94.5M) | (80.6M) | (71.1M) | (63.9M) | (39.7M) |
| Per Share | |||||
| Basic EPS | ($2.38) | ($2.24) | ($1.98) | ($1.87) | ($1.16) |
| Diluted EPS | ($2.38) | ($2.24) | ($1.98) | ($1.87) | ($1.16) |
| Revenue Per Share | $0.23 | $0.25 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 44.8M | 35.9M | 35.9M | 34.2M | 34.2M |
| Diluted Shares Outstanding | 44.8M | 35.9M | 35.9M | 34.2M | 34.2M |
| Profitability Metrics | |||||
| EBITDA | (93.9M) | (79.7M) | (68.6M) | (55.9M) | (39.4M) |
| D&A | 251.0K | 213.0K | 167.0K | 162.0K | 129.0K |
| EBIT | (94.2M) | (79.9M) | (68.7M) | (56.1M) | (39.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026